Amgen Reports Third Quarter 2021 Financial Results

Go back to Amgen Reports Third Quarter 2021 Financial Results

Amgen (AMGN) PT Lowered to $250 at Jefferies

November 3, 2021 8:03 AM EDT

Jefferies analyst Michael Yee lowered the price target on Amgen (NASDAQ: AMGN) to $250.00 (from $270.00) while maintaining a Buy rating.

The analyst commented, "here were, and still are, worries about AMGN numbers, given no big guidance raises all year, and co says ongoing... More

Amgen (AMGN) Tops Q3 EPS by 41c, FY Guidance Tops Consensus

November 2, 2021 4:04 PM EDT

Amgen (NASDAQ: AMGN) reported Q3 EPS of $4.67, $0.41 better than the analyst estimate of $4.26. Revenue for the quarter came in at $6.71 billion versus the consensus estimate of $6.69 billion.

GUIDANCE:

Amgen sees FY2021 EPS of $16.50-$17.10, versus the consensus of $16.43. Amgen sees... More